DDInter1581 DDInter125
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Repaglinide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Asenapine
Repaglinide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Asenapine
Repaglinide {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clozapine
Clozapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluoperazine
Trifluoperazine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quetiapine
Quetiapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluoperazine
Trifluoperazine {u} (Compound) binds {v} (Gene) HRH1
HRH1 {u} (Gene) is bound by {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quetiapine
Quetiapine {u} (Compound) binds {v} (Gene) HRH1
HRH1 {u} (Gene) is bound by {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methdilazine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Asenapine
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluoperazine
Trifluoperazine {u} (Compound) causes {v} (Side Effect) Parkinsonism
Parkinsonism {u} (Side Effect) is caused by {v} (Compound) Asenapine
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Asenapine (Compound)
Repaglinide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Asenapine (Compound)
Repaglinide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Loxapine (Compound) and Loxapine (Compound) resembles Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine and Loxapine (Compound) resembles Asenapine (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) causes Parkinsonism (Side Effect) and Parkinsonism (Side Effect) is caused by Asenapine (Compound)